Login to Your Account



LEAD CANDIDATE PF582 MOVING INTO PHASE III

Lucentis in the crosshairs as Pfenex seeks $74.75M IPO for biosimilar rival

By Marie Powers
Staff Writer

Monday, June 9, 2014

Pfenex Inc. filed with the SEC for an initial public offering (IPO) of up to $74.75 million, aiming to finance a planned phase III trial of lead candidate PF582, a biosimilar to Lucentis (ranibizumab, Genentech Inc./Novartis AG). Filing as an emerging growth company, San Diego-based Pfenex set its sights on the big board, with plans to list on the New York Stock Exchange as PFNX.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription